Ipca Laboratories Limited share price

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropath…Read more

Website NSE BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Midcap 150NSE: IPCALABISIN INE571A01038

16 Oct 2026, 3:30 PM IST₹1,832.60▼ 80.50 (4.21%)

Market Cap₹ 46,494 Cr.
Current Price₹ 1,832.60
High / Low₹ 2,038 / 1,252
Stock P/E35.5
Book Value₹ 318
Dividend Yield0.31 %
ROCE16.4 %
ROE15.20 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 51.63
Price / Book5.77
OPM17.0 %
Debt / Equity0.10
Sales growth (5Y)12.2 %
Profit growth (5Y)0.7 %
Promoter holding45.1 %
EV / EBITDA21.1
Beta0.04
All-time high₹ 2,038

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
IPCALAB	-6.05%	-3.05%	+25.40%	+29.16%	+42.24%	+23.87%	+8.71%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Ipca Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹46,494 crore.
It trades at 35.5 times its last 12 months' earnings and 5.8 times book value.
Revenue grew 12.2% a year over the last 5 years, profit 0.7% a year.
Return on equity was 15.2% and return on capital employed 16.4% in the latest year.
Debt was 0.10 times shareholders' equity.
The share price is 10.1% below its 52-week high and up 42.2% over one year.
Promoters and insiders hold about 45.1%; institutions about 45.7%.

Pros

Latest quarter (Jun 2026): sales up 21% and profit up 82% from a year ago.
Trades at 35.5 times earnings, below its 3-year median of 49.7.
Borrowings are moderate at 0.10 times shareholders' equity.
Institutional (FII + DII) holding has risen by 3.3 points over 3 years.

Cons

Profit growth has been weak: 0.7% a year over the last 5 years.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Ipca Laboratories Limited

Employees: 17,210
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Ipca Laboratories	1,832.60	35.5	46,494	0.31	424	82.18	2,788	20.76	16.4	15.2	5.77	17.0	0.10	45.06	9,646	12.2
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
7.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
8.	Abbott India	26,170.00	34.4	55,609	2.01	429	17.13	1,814	4.33	41.9	34.5	11.65	26.3	0.04	75.54	6,927	9.0
9.	Ajanta Pharma	3,329.00	36.7	41,599	1.91	334	48.37	1,626	38.92	29.4	25.4	9.19	24.5	0.06	54.29	5,407	13.4
10.	Procter & Gamble Health	5,200.00	24.2	8,632	3.01	96	45.29	364	7.37	76.8	61.5	16.46	31.4	0.02	52.19	1,408	8.2
	Median: 13 Co.	2,580.80	33.1	55,609	0.68	505	25.89	3,958	18.81	18.5	16.2	5.05	21.7	0.06	53.24	12,114	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,588	2,034	2,053	2,033	2,093	2,355	2,245	2,247	2,309	2,557	2,393	2,388	2,788
YOY Sales Growth %	0.12%	27.05%	32.79%	34.49%	31.81%	15.78%	9.38%	10.51%	10.33%	8.56%	6.55%	6.31%	20.76%
	1,280	1,713	1,722	1,711	1,700	1,913	1,782	1,818	1,892	2,012	1,859	1,905	2,119
Material Cost %	32%	33%	34%	34%	31%	32%	30%	32%	30%	31%	27%	29%	29%
Employee Cost %	23%	21%	22%	23%	23%	22%	22%	22%	24%	21%	23%	22%	22%
Other Expenses %	26%	30%	28%	28%	27%	27%	28%	27%	28%	27%	27%	28%	26%
Operating Profit	308	321	331	322	393	441	463	429	416	545	533	484	670
OPM %	19%	16%	16%	16%	19%	19%	21%	19%	18%	21%	22%	20%	24%
	45	39	22	19	21	26	20	26	33	28	20	94	25
Exceptional items			68	-137				-205		-58	18	-46
Interest	31	44	33	29	24	23	17	22	19	20	18	20	12
Depreciation	69	90	100	98	99	100	98	100	100	103	108	107	111
Profit before tax	252	225	289	77	290	345	368	128	331	392	446	404	572
	34%	39%	23%	96%	31%	29%	25%	49%	29%	28%	18%	24%	26%
Current tax	83	89	67	72	84	98	101	89	96	108	112	102	133
Deferred tax	2	-1	-0	2	7	1	-10	-27	0	-0	-30	-7	16
	164	136	221	1	199	246	276	64	233	281	364	307	424
Profit from associates	-2	-1	-2	-2	0	0	-1	-2	-2	-3	-0	-3	1
Minority share	1	-9	41	-58	7	16	28	-4	-0	-2	37	8	22
Profit to shareholders	163	145	180	60	192	229	248	68	233	283	326	299	402
YOY Profit Growth %	12.99%	-6.44%	101.42%	-98.30%	21.35%	80.05%	25.05%	4,711.28%	16.95%	14.15%	31.59%	379.28%	82.18%
EPS in Rs	6.42	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,489	1,663	1,507	1,511	1,566	1,811	1,663	1,638	1,747	1,930	1,845	1,814	2,119
YOY Sales Growth %	1.32%	11.97%	5.17%	7.78%	5.18%	8.92%	10.34%	8.46%	11.56%	6.59%	10.98%	10.74%	21.31%
	1,191	1,354	1,233	1,218	1,213	1,409	1,252	1,280	1,340	1,466	1,368	1,383	1,542
Material Cost %	32%	32%	32%	32%	29%	30%	28%	27%	26%	26%	24%	25%	26%
Employee Cost %	22%	20%	22%	22%	23%	21%	22%	23%	23%	21%	23%	23%	22%
Other Expenses %	26%	29%	27%	27%	25%	27%	26%	28%	28%	28%	27%	28%	25%
Operating Profit	298	309	273	292	353	402	411	359	407	465	477	431	578
OPM %	20%	19%	18%	19%	23%	22%	25%	22%	23%	24%	26%	24%	27%
	43	36	17	15	15	17	17	21	25	22	18	30	17
Exceptional items				-94				-282				-30
Interest	31	39	27	24	19	17	10	16	12	11	10	10	5
Depreciation	60	61	63	62	61	63	63	65	63	67	69	70	75
Profit before tax	250	245	200	127	288	339	356	17	357	408	417	350	515
	33%	34%	32%	49%	29%	28%	25%	479%	27%	25%	27%	25%	28%
Current tax	80	84	62	62	81	95	90	76	93	105	111	94	130
Deferred tax	3	-1	1	1	3	1	-2	6	2	-1	3	-7	12
	167	162	137	65	204	244	268	-65	262	305	303	262	373
YOY Profit Growth %	15.83%	-3.37%	13.86%	-23.65%	22.54%	50.57%	95.38%	-200.45%	28.37%	24.83%	13.41%		42.46%
EPS in Rs	6.57	6.39	5.40	2.55	8.05	9.62	10.55	-2.56	10.33	12.01	11.96	10.34	14.71
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	3,284	3,773	4,649	5,420	5,830	6,244	7,705	8,940	9,646	10,126
YOY Sales Growth %		14.91%	23.20%	16.59%	7.56%	7.11%	23.39%	16.02%	7.91%
	2,829	3,081	3,742	3,876	4,521	5,318	6,384	7,213	7,668	7,894
Material Cost %	34%	33%	35%	32%	35%	37%	33%	31%	29%	29%
Employee Cost %	22%	21%	20%	19%	20%	21%	22%	22%	22%	22%
Other Expenses %	29%	28%	25%	21%	23%	28%	27%	27%	28%	27%
Operating Profit	455	692	907	1,544	1,309	927	1,321	1,726	1,979	2,232
OPM %	14%	18%	20%	28%	22%	15%	17%	19%	21%	22%
	42	58	67	63	67	126	125	93	174	167
Exceptional items							-108	-205	-86	-86
Interest	24	19	17	9	8	46	138	85	76	69
Depreciation	178	182	211	209	232	262	357	398	418	429
Profit before tax	295	548	747	1,389	1,136	745	843	1,131	1,573	1,814
	17%	19%	18%	17%	20%	34%	37%	30%	24%	24%
Current tax	62	116	141	249	207	230	310	372	418
Deferred tax	-11	-12	-6	-9	17	23	3	-28	-37
	239	442	604	1,141	890	479	523	785	1,184	1,375
Profit from associates	-4	-2	-8	-8	-21	-13	-6	-2	-8	-5
Minority share		-3	-3	1	6	8	-24	48	43	65
Profit to shareholders		445	606	1,140	884	471	547	738	1,141	1,310
YOY Profit Growth %		84.70%	36.48%	89.07%	-22.03%	-46.17%	9.17%	50.16%	50.75%
EPS in Rs	9.49	17.51	23.89	45.06	34.85	18.58	21.57	29.08	44.98	51.63
Dividend Payout %						22%	9%	14%	5%

Compounded Sales Growth

5 Years:: 12%
3 Years:: 16%
TTM:: 11%

Compounded Profit Growth

5 Years:: 1%
3 Years:: 35%
TTM:: 68%

Stock Price CAGR

5 Years:: 9%
3 Years:: 24%
1 Year:: 42%

Return on Equity

4 Years:: 11%
Last Year:: 15%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	3,219	3,633	4,367	5,399	5,815	6,166	6,678	7,337	7,709
YOY Sales Growth %		12.86%	20.21%	23.63%	7.69%	6.05%	8.29%	9.87%
	2,778	2,940	3,453	4,156	4,903	4,955	5,153	5,556	5,758
Material Cost %	35%	32%	34%	33%	36%	32%	28%	25%	25%
Employee Cost %	22%	21%	20%	20%	21%	22%	22%	23%	22%
Other Expenses %	30%	28%	25%	24%	28%	27%	27%	28%	27%
Operating Profit	442	693	915	1,244	912	1,211	1,525	1,780	1,951
OPM %	14%	19%	21%	23%	16%	20%	23%	24%	25%
	40	55	65	56	111	111	71	95	87
Exceptional items						-133	-282	-30	-30
Interest	24	18	16	7	44	121	63	44	36
Depreciation	174	172	179	204	229	246	252	269	280
Profit before tax	283	557	785	1,088	750	822	1,000	1,532	1,691
	18%	18%	17%	20%	33%	35%	35%	26%	26%
Current tax	60	115	138	197	224	288	341	402
Deferred tax	-10	-12	-5	20	21	4	8	-3
	233	455	652	871	506	530	651	1,133	1,244
YOY Profit Growth %		95.15%	43.43%	33.49%	-41.94%	4.89%	22.69%	74.03%
EPS in Rs	9.24	18.01	25.82	34.33	19.39	20.91	25.65	44.64	49.02
Dividend Payout %					20%	10%	16%	5%

Compounded Sales Growth

5 Years:: 11%
3 Years:: 8%
TTM:: 12%

Compounded Profit Growth

5 Years:: 12%
3 Years:: 31%
TTM:: 76%

Stock Price CAGR

5 Years:: 9%
3 Years:: 24%
1 Year:: 42%

Return on Equity

4 Years:: 11%
Last Year:: 15%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	25	25	25	25
Reserves	5,817	6,307	6,923	8,038
	1,481	1,438	1,363	809
Long term borrowings	652	580	543	109
Short term borrowings	806	807	758	595
	1,303	3,331	3,449	3,498
Trade payables	525	776	846	940
Minority interest	73	1,395	1,440	1,460
Current liabilities	1,806	2,356	2,386	2,307
Total Liabilities	8,626	11,101	11,761	12,370
	2,732	4,696	4,763	5,271
Gross block	4,162	6,949	7,337	8,163
Accumulated depreciation	1,431	2,253	2,575	2,892
Goodwill & intangibles	197	233	203	198
CWIP	159	357	694	830
	5,736	6,049	6,304	6,269
Inventories	1,743	2,471	2,560	2,731
Trade receivables	989	1,687	1,884	2,014
Cash & equivalents	1,258	209	167	437
Current assets	5,189	5,539	6,269	6,377
Total Assets	8,626	11,101	11,761	12,370

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	806	945	1,321	1,142
Profit for the year	471	547	738	1,141
Working capital changes	49	-92	-176	-294
Direct taxes paid	-224	-296	-361	-414
	-725	-1,292	-870	-247
Fixed assets purchased	-494	-411	-776	-656
Fixed assets sold	36	9	5
Investments purchased			-103
Investments sold		65		55
	507	-553	-283	-754
Proceeds from borrowings	392	124	218
Repayment of borrowings	-28	-177	-248	-525
Interest paid	-41	-134	-74	-82
Dividends paid	-101	-51	-101	-52
Net Cash Flow	588	-900	169	142
Free Cash Flow	311	533	546	486

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	8.1%	9.0%	11.1%	15.2%
ROCE	—	11.6%	11.2%	13.0%	16.4%
Operating margin	—	11.4%	12.3%	15.3%	17.0%
Net margin	—	7.6%	7.2%	8.3%	11.9%
Debt / equity	—	0.25	0.23	0.20	0.10
Current ratio	—	2.87	2.35	2.63	2.76

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities).

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 44.72%
FIIs 11.53%
DIIs 36.59%
Public 7.15%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	46.29%	46.30%	46.30%	46.30%	44.72%	44.72%	44.72%	44.72%	44.72%	44.72%	44.72%	44.72%
	10.27%	10.51%	10.85%	10.83%	11.07%	10.76%	10.67%	10.43%	10.63%	10.63%	10.73%	11.53%
Foreign portfolio investors (Cat. I)	10.03%	10.23%	10.56%	10.46%	10.45%	10.37%	10.37%	10.15%	10.34%	10.31%	10.34%	11.19%
Foreign portfolio investors (Cat. II)	0.24%	0.28%	0.29%	0.37%	0.61%	0.38%	0.30%	0.27%	0.28%	0.32%	0.38%	0.33%
	34.52%	34.37%	33.78%	34.23%	35.68%	36.06%	36.20%	36.77%	37.32%	37.45%	37.37%	36.59%
Mutual funds	29.25%	28.83%	28.52%	28.55%	29.63%	29.63%	29.61%	30.04%	30.52%	31.24%	31.15%	31.07%
Insurance companies	4.54%	4.67%	4.63%	4.87%	5.19%	5.64%	5.83%	5.99%	6.15%	5.34%	5.24%	4.76%
Banks		0.01%	0.01%
Alternative investment funds	0.40%	0.54%	0.30%	0.48%	0.54%	0.46%	0.44%	0.42%	0.32%	0.55%	0.65%	0.45%
	8.92%	8.82%	9.06%	8.64%	8.53%	8.46%	8.41%	8.07%	7.33%	7.20%	7.18%	7.15%
Retail (up to ₹2 lakh)	7.12%	7.13%	7.27%	6.93%	6.88%	6.81%	6.82%	6.55%	5.88%	5.79%	5.76%	5.72%
NRIs	0.45%	0.44%	0.47%	0.46%	0.46%	0.46%	0.46%	0.45%	0.39%	0.38%	0.37%	0.37%
Bodies corporate	0.47%	0.43%	0.57%	0.47%	0.45%	0.47%	0.42%	0.37%	0.34%	0.33%	0.34%	0.38%
IEPF	0.30%	0.30%	0.30%	0.30%	0.31%	0.31%	0.31%	0.31%	0.35%	0.34%	0.33%	0.32%
No. of Shareholders	82,809	81,165	84,753	82,975	90,189	88,306	85,582	82,870	77,673	82,184	82,060	90,514

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 12 Nov 2026
Ex-dividend date: 7 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Ipca Laboratories Limited

What is the share price of Ipca Laboratories Limited today?

Ipca Laboratories Limited (IPCALAB) last traded at ₹1,832.60 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Ipca Laboratories Limited?

About ₹46,494 crore at the latest price.

What is the P/E ratio of Ipca Laboratories Limited?

About 35.5 times its earnings over the last 12 months.

Is Ipca Laboratories Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Ipca Laboratories Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Ipca Laboratories Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Ipca Laboratories Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Ipca Laboratories Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next